However, the percentage of CD4+ T cells was significantly decreased in tumor samples (54.7 ± 19.6%) and mucosa (45.3 ± 28.6%) compared to PBMC HNSCC (66.6 ± 15.9%; p < 0.05; Figure 1B, middle plot). This evidence concerns the gene CD4 and head and neck squamous cell carcinoma.